Analyte Health Teams with IQuity To Make Innovative Tests Available

Analyte Health, a leading platform connecting patients to diagnostic services, announced today that they have partnered with IQuity, Inc., to make available that organization’s innovative diagnostic tests to qualified patients.

Through the partnership, qualified patients will immediately be able to access IQuity’s unique, patented diagnostic test, IsolateMS™, to assist their providers in determining whether they might be suffering from multiple sclerosis.

The IsolateMS test is just one of the tests that will be made available via Analyte Health’s “Health Test Express” website.

“Analyte Health is the leading independent company helping consumers better manage their health through increased access to and understanding of lab diagnostic information. We’re excited that more patients can now benefit from IQuity’s cutting edge science,” said Analyte Health CEO Kevin Weinstein.

IQuity’s breakthrough RNA analytic process, IQIsolate™, gives providers a new tool to confirm a suspected autoimmune diagnosis with accuracy greater than 90% and help patients at the earliest sign of symptoms.

IQuity’s CEO, Chase Spurlock, PhD, also noted that “As we launched the IsolateMS test, we were looking for clinically appropriate ways to make the test widely available to patients. In addition to our efforts working directly with leading, traditional physician groups, we actively sought out other innovative partners to raise awareness directly with patients. Analyte Health’s unique combination of capabilities is the perfect way to introduce our tests to a broader audience. Our mission is to help as many as patients as possible, and Analyte Health offers us the chance to do just that.”

To learn more, click here.

This post was written by:

- who has written 371 posts on mHealthWatch.

Contact the author